对吡啶基硫脲 | 164670-44-4

• 物质功能分类: 化学试剂 - 有机试剂 - 硫脲
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 对吡啶基硫脲
• 中文别名: 4-吡啶基硫脲；4-吡啶硫脲；N-(4-吡啶基)硫脲
• 英文名称: 1-(pyridin-4-yl)thiourea
• 英文别名: (pyridin-4-yl)thiourea；N-(4-pyridyl)thiourea；pyridin-4-yl-thiourea；4-pyridylthiourea；1-(4-pyridyl)-2-thiourea；γ-Pyridyl-thioharnstoff；N'-pyridin-4-ylcarbamimidothioic acid
• CAS: 164670-44-4
• 化学式: C₆H₇N₃S
• mdl: MFCD00068177
• 分子量: 153.208
• InChiKey: HLOFIQOOOSRNFY-UHFFFAOYSA-N

物化性质

• 熔点：
  174 °C
• 沸点：
  298.7±32.0 °C(Predicted)
• 密度：
  1.382±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  避氧化物

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xn
• 安全说明：
  S22,S36/37
• 危险类别码：
  R20/21/22
• 危险品运输编号：
  2811
• 海关编码：
  2933399090
• 包装等级：
  III
• 危险类别：
  6.1

SDS

Name:	n-(4-Pyridyl)thiourea 97% Material Safety Data Sheet
Synonym:
CAS:	164670-44-4

Section 1 - Chemical Product MSDS Name:n-(4-Pyridyl)thiourea 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
164670-44-4	N-(4-Pyridyl)thiourea	97%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. May cause respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 164670-44-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white - yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 181 - 184 deg C(decom)
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6H7N3S
Molecular Weight: 153

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Not available.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 164670-44-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
N-(4-Pyridyl)thiourea - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 36/37 Wear suitable protective clothing and
gloves.
WGK (Water Danger/Protection)
CAS# 164670-44-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 164670-44-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 164670-44-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

吡啶基硫脲可用作化工和医药合成的中间体，例如N-吡啶-4-基-哌嗪-1-甲脒三氟乙酸盐。

制备

对吡啶基硫脲的制备步骤如下：首先将1,1-硫代羰基二咪唑（29.4克，0.16摩尔）加入到无水四氢呋喃（600毫升）中溶解4-氨基吡啶（14.1克，0.15摩尔），然后搅拌混合物17小时。接着在减压下除去溶剂，并将得到的固体悬浮于二氯甲烷和水的混合物中。过滤未溶解的固体并用丙酮洗涤，最终获得固体产物（8.98克）。接下来，将气态氨通入无水四氢呋喃（250毫升）溶液中的对吡啶基硫脲固体产物（8.50克，0.06摩尔），搅拌20分钟后停止氨流。继续搅拌17小时，在此过程中会形成沉淀物。随后过滤并真空干燥所得固体，最终得到所需的硫脲产品——对吡啶基硫脲（5.1克）。

反应信息

• 作为反应物：
  描述：

  对吡啶基硫脲 在 溴 、 溶剂黄146 作用下， 以 1,4-二氧六环 为溶剂， 生成 3-[2-(Pyridin-4-ylamino)-5-[1,2,4]triazol-1-yl-thiazol-4-yl]-benzonitrile
  参考文献：
  名称：

  A new orally bioavailable dual adenosine A2B/A3 receptor antagonist with therapeutic potential

  摘要：

  The synthesis and SAR of 5 -heterocycle- substituted aminothiazole adenosine receptor antagonists is described. Several compounds show high affinity and selectivity for the A(2B) and A(3) receptors. One compound (5f) shows good ADME properties in the rat and as such may be an important new compound in testing the current hypotheses proposing a therapeutic role for a dual A(2B)/A(3) antagonist in allergic diseases. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.04.021
• 作为产物：
  描述：

  1-benzoyl-3-pyridin-4-yl-thiourea 在 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 对吡啶基硫脲
  参考文献：
  名称：

  取代的N-苯基异硫脲：具有神经元同工型选择性的人一氧化氮合酶的有效抑制剂。

  摘要：

  已经发现S-乙基N-苯基异硫脲（4）是一氧化氮合酶的人组成型和诱导型同工型的有效抑制剂。合成了一系列取代的N-苯基异硫脲类似物，以研究这类抑制剂的构效关系。评价每种类似物的人同工型选择性。一种类似物S-乙基N- [4-（三氟甲基）苯基]异硫脲（39）对神经元同工型的诱导选择性和对内皮衍生的组成型同工型的选择性分别为115倍和29倍。研究表明，取代的N-苯基异硫脲39与L-精氨酸竞争性结合。

  DOI：

  10.1021/jm960785c

文献信息

• [EN] THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE<br/>[FR] DÉRIVÉS DE THIOPHÈNE POUR LE TRAITEMENT DE TROUBLES PROVOQUÉS PAR IGE
  申请人：UCB BIOPHARMA SRL

  公开号：WO2019243550A1

  公开（公告）日：2019-12-26

  Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.

  提供了公式（I）的噻吩衍生物及其药用可接受的盐。这些化合物对于治疗或预防由IgE引起的疾病具有用途，如过敏、1型超敏反应或家族性鼻窦炎。
• [EN] PYRIDINYL DERIVATIVES AS INHIBITORS OF ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE<br/>[FR] DÉRIVÉS DE PYRIDINYLE UTILISÉS EN TANT QU'INHIBITEURS DE L'ENZYME NICOTINAMIDE PHOSPHORIBOSYLTRANSFÉRASE
  申请人：TOPOTARGET AS

  公开号：WO2010142735A1

  公开（公告）日：2010-12-16

  The present application discloses a compound of the formula (I) wherein Q is optionally substituted pyridyl; p is 0-6; Y is formulae (i), (ii) and (iii) where X is =O, =S and =N-CN, r is 1-12, R is -Z-A, Z is a single bond, -S(=O)2-, >P=O, >C=O, -C(=O)NH-, and -C(=S)NH-; and A is hydrogen, C1-12-alkyl, C3-12-cycloalkyl, - [CH2CH2O]1-10-(C1-6-alkyl), C1-12-alkenyl, aryl, heterocyclyl, and heteroaryl; B is a single bond, -NRN-, -S(=O)2- and -O-; wherein RN is selected from hydrogen, C1-12-alkyl, C3-12-cycloalkyl, -[CH2CH2O]1-10-(C1-6-alkyl), C1-12-alkenyl, aryl, heterocyclyl, and heteroaryl; s is 0-6; and Cy is aryl, cycloalkyl, heterocyclyl, and heteroaryl. The compounds are usefuld for use as a medicament for the treatment of a disease or a condition caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPRT).

  本申请公开了一种化合物，其化学式为（I），其中Q是可选择取代的吡啶基；p为0-6；Y是式（i）、（ii）和（iii），其中X为=O、=S和=N-CN，r为1-12，R为-Z-A，Z为单键，-S(=O)2-，>P=O，>C=O，-C(=O)NH-和-C(=S)NH-；A为氢、C1-12-烷基、C3-12-环烷基、-[CH2CH2O]1-10-(C1-6-烷基)、C1-12-烯基、芳基、杂环烷基和杂芳基；B为单键，-NRN-，-S(=O)2-和-O-；其中RN从氢、C1-12-烷基、C3-12-环烷基、-[CH2CH2O]1-10-(C1-6-烷基)、C1-12-烯基、芳基、杂环烷基和杂芳基中选择；s为0-6；Cy为芳基、环烷基、杂环烷基和杂芳基。这些化合物可用作治疗由烟酰胺磷酸核糖转移酶（NAMPRT）水平升高引起的疾病或症状的药物。
• Synthesis and Evaluation of the 2-Aminothiazoles as Anti-Tubercular Agents
  作者：Edward A. Kesicki、Mai A. Bailey、Yulia Ovechkina、Julie V. Early、Torey Alling、Julie Bowman、Edison S. Zuniga、Suryakanta Dalai、Naresh Kumar、Thierry Masquelin、Philip A. Hipskind、Joshua O. Odingo、Tanya Parish

  DOI：10.1371/journal.pone.0155209

  日期：——

  designing and synthesizing a large number of analogs and testing these for activity against M. tuberculosis, as well as eukaryotic cells. We determined that the C-2 position of the thiazole can accommodate a range of lipophilic substitutions, while both the C-4 position and the thiazole core are sensitive to change. The series has good activity against M. tuberculosis growth with sub-micromolar minimum

  2-氨基噻唑系列对全球重要病原体结核分枝杆菌具有抗菌活性。我们通过设计和合成大量类似物并测试它们对结核分枝杆菌以及真核细胞的活性来探索其活性的本质。我们确定噻唑的 C-2 位可以容纳一系列亲脂性取代，而 C-4 位和噻唑核心都对变化敏感。该系列对结核分枝杆菌生长具有良好的活性，可达到亚微摩尔的最低抑制浓度。与其他细菌相比，代表性的类似物对分枝杆菌物种具有选择性，并且对复制的结核分枝杆菌具有快速杀菌作用。作用方式似乎不涉及铁螯合。我们的结论是，该系列作为新型抗结核药物具有进一步开发的潜力。
• BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION
  申请人：JACKSON Paul Francis

  公开号：US20120129842A1

  公开（公告）日：2012-05-24

  This invention relates to bisthiazole I and its therapeutic and prophylactic uses, wherein the variables A, R 5 , R 6 , and R 7 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

  本发明涉及双噻唑I及其治疗和预防用途，其中变量A，R 5 ，R 6 ，和R 7 在说明书中定义。治疗的和/或预防的疾病包括类风湿性关节炎。
• 18-Crown-6 Catalyzed Microwave-mediated Synthesis of Symmetric Bis-Heterocyclic Compounds under Solvent-free Condition
  作者：Rathnasamy Rishikesan、Kamalakannan Prabakaran、Rajamani Murugesan、Ramaswamy Venkataraman、Pakkath Karuvalam Ranjith、Sivasubramanian Arvind、Sathiah Thennarasu

  DOI：10.1002/jhet.2162

  日期：2015.9

  An efficient, solvent‐free and 18‐crown‐6 catalyzed method for the synthesis of N‐alkyl‐4‐(4‐(5‐(2‐(alkyl‐amino)thiazol‐4‐yl)pyridin‐3‐yl)phenyl)thiazol‐2‐amine, N‐alkyl‐4‐(5‐(2‐alkyamino)thiazol‐4‐yl)pyridine‐3‐yl)thiazol‐2‐amine, and 4,4′‐bis‐2‐[amino]‐4‐thiazolyl}biphenyl bis‐heterocyclic derivatives via microwave accelerated cyclization is presented.

  合成N-烷基-4-（4-（5-（2-（烷基-氨基）噻唑-4-基）吡啶-3-基）的高效，无溶剂和18冠冕6催化方法苯基）噻唑-2-胺，N-烷基-4-（5-（2-烷基氨基）噻唑-4-基）吡啶-3-基）噻唑-2-胺和4,4'-双2介绍了通过微波加速环化反应生成的[[氨基] -4-噻唑基}联苯双杂环双杂环衍生物。